BioVersys Extends its Series C Round to CHF 32.6 Million with Investment from the AMR Action Fund

BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investmentBASEL, Switzerland, January 05, 2023 / B3C newswire / -- BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research a...

Related Keywords

Switzerland ,Swiss ,Marc Gitzinger ,Carly Levine ,Martin Heidecker ,Eliane Schmidt ,Seng Chin Mah ,University Of Lille ,Linkedin ,Action Fund ,Twitter ,Chief Executive Officer ,Chief Investment Officer ,Executive Assistant ,Financial Management ,Infectious Disease Medicine ,Bacterial Infections ,Anti Bacterial Agents ,Critical Care ,Drug Resistance ,Cross Infection ,Healthcare Associated Pneumonia ,Pharmaceutical Preparations ,